Gastrointestinal Cancer

Douglas A. Nelson, MD, discusses the future utility of circulating tumor DNA in colorectal cancer.

Diane M. Simeone, MD, discusses the importance of germline testing in pancreatic cancer.

Tannaz Armaghany, MD, discusses the utility of circulating tumor DNA in colorectal cancer.

Heinz-Josef Lenz, MD, FACP, discusses the updated findings from the phase 2 CheckMate-142 trial in previously untreated patients with microsatellite instability–high (MSI-H)/mismatch repair deficient (dMMR) metastatic colorectal cancer (mCRC).

The European Commission has approved encorafenib (Braftovi) in combination with cetuximab (Erbitux) for the treatment of adult patients with BRAF V600E–mutant metastatic colorectal cancer who have received prior systemic therapy.

Scott Kopetz, MD, PhD, FACP, discusses the latest findings from the BEACON CRC study, the importance of testing for BRAF mutations in patients with CRC, and future directions with these agents.

Thierry Andre, MD, discusses the rationale for the phase 3 KEYNOTE-177 trial in metastatic colorectal cancer.

Michael J. Overman, MD, discusses potential applications for circulating tumor DNA in colorectal cancer.

Tanios S. Bekaii-Saab, MD, FACP, discusses the growing role of targeted therapy in CRC.